[SCHEDULE 13G] Aligos Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

This Schedule 13G discloses that Sio Capital Management, LLC beneficially owned 355,937 shares of Aligos Therapeutics common stock, representing 5.49% of the class. The filing states these shares are held by affiliated funds for which Sio acts as a registered investment adviser, and that Sio has shared voting and shared dispositive power over the reported shares while having no sole voting or dispositive power. The percentage is calculated using 6,114,801 shares outstanding as reported in the issuer's 10-Q. Item 10 certifies the position was acquired and is held in the ordinary course of business and not to influence control. The filing also notes that Sio and its GP are controlled by Michael Castor, though any beneficial ownership by the GP or Mr. Castor is expressly disclaimed.

Positive

• Sio Capital beneficially owns 355,937 shares, representing a material 5.49% stake that signals institutional interest in ALGS.
• Item 10 certification

Negative

• No sole voting or dispositive power is reported; Sio's influence is shared rather than unilateral.
• Attribution language noting control by Michael Castor combined with an express disclaimer may create ambiguity about ultimate beneficial ownership for governance analysis.

Insights

Financial Analyst

TL;DR: A 5.49% passive stake signals meaningful institutional interest without an activist control bid.

Sio Capital's holding of 355,937 shares (5.49%) is large enough to attract investor attention but the filing consistently frames the position as passive: shared voting/dispositive power and the Item 10 certification that the stake was acquired in the ordinary course and not to influence control. For market impact, a disclosed >5% stake can prompt trading or analyst inquiry, yet absent additional purchases, governance proposals, or coordination with other holders this filing alone is unlikely to change corporate strategy or control dynamics.

Corporate Governance Expert

TL;DR: Shared power and GP control language create attribution questions despite the explicit disclaimer.

The Schedule 13G notes shared voting and dispositive power and explains that Sio and Sio GP, LLC act for funds that are record owners. It further discloses that both entities are controlled by Michael Castor, but then expressly disclaims beneficial ownership by the GP or Mr. Castor. This mix of attribution language and disclaimer is common, yet it can create ambiguity for governance-focused investors assessing potential influence. The filing's Item 10 certification supports a passive intent, consistent with a 13G filing rather than an active 13D approach.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aligos Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value, $0.0001 per share

(Title of Class of Securities)

01626L204

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 01626L204

1

Names of Reporting Persons

Sio Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 355,937.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 355,937.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

355,937.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.49 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: 1 As of June 30, 2025, Sio Capital Management, LLC beneficially owned 355,937 shares of Common Stock with shared voting power and shared dispositive power. 2 Based upon 6,114,801 Common Shares outstanding as of May 1, 2025, as disclosed by the Issuer's 10-Q on May 6, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aligos Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: One Corporate Drive, 2nd Floor, South San Francisco, California 94080
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
(b)	Address or principal business office or, if none, residence: 600 Third Avenue, 2nd Floor New York, New York 10016
(c)	Citizenship: Sio is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value, $0.0001 per share
(e)	CUSIP No.: 01626L204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 355,937
(b)	Percent of class: 5.49%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 355,937 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 355,937 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sio Capital Management, LLC

Signature:	/s/ Jin W. Lee
Name/Title:	Chief Compliance Officer
Date:	08/13/2025

FAQ

How many Aligos (ALGS) shares does Sio Capital own?

355,937 shares of Aligos common stock are reported as beneficially owned by Sio Capital Management, LLC.

What percentage of ALGS does Sio Capital's holding represent?

The filing reports the position represents 5.49% of the outstanding common stock.

Does Sio Capital have sole voting power over the shares?

No. The filing reports 0 shares with sole voting power and 355,937 shares with shared voting power.

Was the stake acquired to influence control of Aligos?

According to Item 10, the securities were acquired and are held in the ordinary course of business and were not acquired to influence control.

What outstanding share count is the percentage based on?

The percentage calculation is based on 6,114,801 common shares outstanding as disclosed in the issuer's 10-Q.

Who else is mentioned as potentially related to this ownership?

The filing states that Sio and Sio GP, LLC are controlled by Michael Castor, but any beneficial ownership by the GP or Mr. Castor is expressly disclaimed.